Intravesical thio-tepa: a study of 3H-thymidine uptake in normal urothelium and FANFT-induced tumors in rats.
Treatment of superficial low-grade bladder cancer often incorporates intravesical instillations of the alkylating agent thio-TEPA. Current dosages and administration schedules are empiric inasmuch as cytokinetic data are sparse. The FANFT-induced bladder rat tumor model closely approximates human bladder cancer. This study measuring 3H-thymidine uptake identified peaks of maximal synthetic activity at 3 and 9 days after thio-TEPA exposure in both normal and neoplastic urothelium. Thus, repeat instillation at these intervals may improve cytotoxicity and overall response rate.
D000818:Animals; D001345:Autoradiography; D002295:Carcinoma, Transitional Cell / Q000139:chemically induced / Q000188:drug therapy* / Q000378:metabolism; D004273:DNA, Neoplasm / Q000096:biosynthesis; D004848:Epithelium / Q000187:drug effects / Q000473:pathology; D005200:FANFT; D005260:Female; D009374:Neoplasms, Experimental / Q000139:chemically induced / Q000188:drug therapy / Q000378:metabolism; D051381:Rats; D012588:Scintillation Counting; D013852:Thiotepa / Q000008:administration & dosage / Q000627:therapeutic use*; D013936:Thymidine / Q000378:metabolism; D001743:Urinary Bladder / Q000187:drug effects / Q000378:metabolism; D001749:Urinary Bladder Neoplasms / Q000139:chemically induced / Q000188:drug therapy* / Q000378:metabolism
D004273:DNA, Neoplasm; D005200:FANFT; D013852:Thiotepa; D013936:Thymidine